Please assess the completion status of the following clinical trial:

Trial Title: Effect of Darbepoetin in Contrast-induced Nephropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age over 18 yr~* estimated glomerular filtration rate (GFR) \< 60 ml/min/1.73m2~Exclusion Criteria:~* Chronic renal replacement therapy (hemodialysis, peritoneal dialysis, continuous renal replacement therapy)~* Pregnancy or lactation~* Use of contrast agent within 1 week~* Emergent CAG or PCI~* Not recovered from AKI(acute kidney injury)~* Use of nephrotoxic drugs within 48 hr~* Cardiogenic shock (SBP(systolic blood pressure) \< 90 mmHg) or pulmonary edema~* Uncontrolled hypertension (SBP ≥ 200 mmHg or DBP(diastolic blood pressure) ≥ 130 mmHg)~* History of hypersensitivity to contrast agent~* Known allergy or hypersensitivity to EPO(erythropoietin)~* Use of EPO within 1 month~* Anemia (hemoglobin \< 9 g/dL)~* Ventilatory care

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- darbepoetin-α (Type: EXPERIMENTAL): Infusion of darbepoetin-α 1.5 μg/kg will be performed 1 hour before angiography
- isotonic saline (Type: PLACEBO_COMPARATOR): Infusion of isotonic saline will be performed 1 hour before angiography

Based on this trial design, predict the completion outcome and termination type (if applicable).